Staidson announced on December 21 that, in order to implement the company's development strategy, optimize internal resources and asset structure, and support the development of its subsidiaries, the company plans to use the gene therapy and cell therapy platforms already established by Beijing SoloBio Genetechnology Company Ltd. (hereinafter referred to as "SoloBio") as a technical foundation. The company will transfer the relevant assets of the hepatitis B and other infectious disease pipeline projects to its wholly-owned subsidiary at book value, and authorize the company’s management to handle matters related to the asset transfer.
Staidson(Beijing)Biopharmaceuticals Co.,Ltd. set November 30, 2022 as the transfer benchmark date, and transferred the related assets of its existing hepatitis B and other infectious disease pipeline projects, with a book net value of approximately 24.39 million yuan, to SoloBio. At the same time, the company plans to transfer patents, contracts, and other related rights and obligations associated with the aforementioned projects to SoloBio based on actual conditions. Any asset changes occurring between the transfer benchmark date and the actual transfer date will be adjusted by the company according to the actual situation, and the final transferred assets will be determined by the implementation results of the transfer.
This asset transfer is an asset transfer between the company and its wholly-owned subsidiary, conducted within the scope of the company's consolidated financial statements, without involving any changes in the scope of the consolidated financial statements. It will not have a significant impact on the company’s financial condition and operating results, nor will it harm the interests of the company and its shareholders.